New study tracks Real-World use of teplizumab to delay type 1 diabetes
NCT ID NCT07457580
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study observes 60 people with stage 2 type 1 diabetes who received teplizumab as part of managed access programs. Researchers will review medical records to describe patient characteristics, monitoring practices, and how long it takes for diabetes to progress. The goal is to gain rapid insight into how teplizumab is being used in real-world clinical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teplizumab
What this could lead to
If successful, this study could help doctors better understand which patients benefit most from teplizumab and how it affects diabetes progression in real-world settings.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by small sample size and variability in real-world care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 0560001
RECRUITINGLeuven, 3000, Belgium
-
Investigational Site Number: 2500001
RECRUITINGBron, 69677, France
-
Investigational Site Number: 2500002
RECRUITINGParis, 75015, France
-
Investigational Site Number: 2500003
RECRUITINGParis, 75014, France
-
Investigational Site Number: 3800001
RECRUITINGAncona, 60123, Italy
-
Investigational Site Number: 3800003
RECRUITINGPalermo, 90127, Italy
-
Investigational Site Number: 7240001
RECRUITINGMadrid, 28034, Spain
-
Investigational Site Number: 7240002
RECRUITINGMadrid, 28046, Spain
-
Investigational Site Number: 7240003
RECRUITINGZaragoza, 50009, Spain
-
Investigational Site Number: 8260001
RECRUITINGBirmingham, B4 6NH, United Kingdom
-
Investigational Site Number: 8260002
RECRUITINGLondon, E1 1BB, United Kingdom